According to Madewell et al. [31], Bcl-2 was also frequently expressed in FMCs, it concerned 13 out of the 15 invasive mammary carcinomas, (i.e., 86.7% of the studied carcinomas) with Bcl-2-positive carcinomas containing 20–80% of immunolabeled cells. The gene discussed is BCL2; the disease is invasive breast carcinoma.